Press Releases

Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program
September 13, 2021

Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH
September 10, 2021

Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
July 23, 2021

Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
July 13, 2021

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
June 25, 2021

Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
June 09, 2021

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
May 06, 2021

Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
April 29, 2021

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
March 23, 2021

Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
March 22, 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
March 11, 2021

Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
February 18, 2021

Hepion Pharmaceuticals Announces Pricing of Public Offering
February 16, 2021

Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2021

Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
February 10, 2021

Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
February 09, 2021

Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
January 05, 2021

Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
December 22, 2020

Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
December 10, 2020

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease
December 02, 2020

Hepion Announces Closing of Public Offering of Common Stock
November 30, 2020

Hepion Pharmaceuticals Prices Public Offering
November 24, 2020

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
November 18, 2020

Hepion Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
November 17, 2020

Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020
November 12, 2020

Hepion Pharmaceuticals Completes First Cohort Enrollment in Phase 2a 'AMBITION' Clinical Trial
November 10, 2020

Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020
October 27, 2020

Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team
October 05, 2020

Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
September 29, 2020

Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases
September 17, 2020

Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
September 01, 2020

Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM)
August 27, 2020

Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431's Antiviral Properties
August 12, 2020

Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial
August 05, 2020

Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
July 07, 2020

Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
June 29, 2020

Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis
June 22, 2020

Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
June 10, 2020

Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
May 20, 2020

Hepion Pharmaceuticals' CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis
May 19, 2020

Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study
March 12, 2020

Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases
February 19, 2020

Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
February 12, 2020

Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study
January 28, 2020

Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference
January 08, 2020

Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs
January 06, 2020

Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
December 10, 2019

Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019
December 09, 2019

Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments
December 03, 2019

Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
December 03, 2019

Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
November 20, 2019

Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
November 07, 2019

Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH
November 07, 2019

Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
October 23, 2019

Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases
October 16, 2019

World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director
October 10, 2019

Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions
October 03, 2019

Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference
September 04, 2019